OnCore Login

Return to Trial Database

HCRN-GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

 

Status

Study Completed

Cancer Type(s)

BladderUrothelial Carcinoma

Study Contact

Publications

Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma
  • N Adra, RJ Hauke, HZ Kaimakliotis, S Gulati, N Hashemi, R Pili

Trial Locations

All sites in which the trial HCRN-GU17-295 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278